Canadian Cardiovascular Society Antiplatelet Guidelines

Slides:



Advertisements
Similar presentations
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY Working Group:
Advertisements

Leadership. Knowledge. Community. Antiplatelet Therapy for the Primary Prevention of Vascular Events Working Group: Alan D. Bell, MD, CCFP and James D.
RECOMMENDATIONS Canadian Cardiovascular Society Anti Platelet Guideline 2010 Alan D. Bell, MD, CCFP; Raymond Cartier, MD; Wee Shian Chan, MD, FRCP; James.
Leadership. Knowledge. Community. Guideline Pearls Canadian Cardiovascular Society Antiplatelet Guidelines.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines INTERACTION BETWEEN CLOPIDROGEL AND PROTON PUMP INHIBITORS Working.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines MANAGEMENT OF ANTIPLATELET THERAPY IN ASSOCIATION WITH MINOR.
Leadership. Knowledge. Community. Introduction Canadian Cardiovascular Society Antiplatelet Guidelines.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Canadian Cardiovascular Society Antiplatelet Guidelines
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
Medications that impact bleeding By Nino Lalaiants Inesa Legrian NYCCT 2012.
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
Antiplatelet therapy in CAD MINILECTURE. Objectives Indications for Antiplatelet Therapy in patients with CAD and ACS Antiplatelet Therapy in the role.
Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention Beyond One Year Following ACS or PCI Working Group: Anil Gupta MD, FRCPC,
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines Antiplatelet Therapy for Vascular Prevention in Patients with.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Secondary prevention after a TIA or ischemic stroke.
Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
Clopidogrel Audit Vikas Jasoria December What is it? Clopidogrel is a thienopyridine antiplatelet drug which reduces platelet aggregation by inhibiting.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
The Primary and Secondary Prevention of Cardiovascular Disease Per Olav Vandvik, MD, PhD A. Michael Lincoff, MD Joel M. Gore, MD David Gutterman, MD, FCCP.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Rikki Weems, PGY III August 20, 2015
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Acute Coronary Syndrome: In Hospital Antiplatelet Management
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
The Primary and Secondary Prevention of Cardiovascular Disease
_________________ Caitlin M. Gibson, PharmD, BCPS
The management of anti-thrombotics in patients undergoing GI endoscopy
Disclosures Speaker’s bureau: Research support: Consulting: Equity
Stent Thrombosis and Optimal Duration of DAPT
Denise Sutter, PharmD, BCPS
Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.
Randomisation before planned PCI with DES (n=2500)
Polypharmacy Anticoagulation: AF meets PCI
Proposed use of P2Y12 inhibitors
ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.
Ischaemic Heart Disease Acute Coronary Syndrome
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.
Achieving Long-Term Protection Post-MI
Gilles Montalescot, ACTION Study Group, Paris
The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines  Alan D. Bell, MD, CCFP, André Roussin, MD, FRCPC,
Glenn N. Levine et al. JACC 2016;68:
Dabigatran in myocardial injury after noncardiac surgery
Antiplatelet Therapy and Secondary Prevention
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Terms of Use. Terms of Use.
NOACS: Emerging data in ACS/IHD
AF and PCI in Practice.
ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.
Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy  Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,
What oral antiplatelet therapy would you choose?
Elevated Admission Plasma Glucose Following ACS
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
Factor Xa Inhibitors in Coronary Artery Disease
Roberta Rossini et al. JCIN 2018;11:
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
ESC Guideline on the Management of STEMI Recommendation for DAPT
Section C: Clinical trial update: Oral antiplatelet therapy
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

Canadian Cardiovascular Society Antiplatelet Guidelines Guideline Pearls 1

Objective To interpret a quick summary of the key “takeaways” from the Canadian Cardiovascular Society Antiplatelet Guidelines. © 2011 - TIGC

Guideline Pearls Do’s and Don’ts Primary prevention DO DON’T Consider ASA only where there is clear evidence of high risk. Asymptomatic carotid stenosis Asymptomatic coronary atherosclerosis Reduced ABI Use antiplatelet therapy for primary prevention. © 2011 - TIGC

Guideline Pearls Do’s and Don’ts Cerebrovascular disease DO DON’T Provide lifetime antiplatelet Rx to all patients post ischemic stroke or TIA. Consider DAPT with ASA + Clopidogrel in patients with high risk TIA or minor stroke for 30 days. Use DAPT with ASA + Clopidogrel for long term secondary stroke prevention. © 2011 - TIGC

Guideline Pearls Do’s and Don’ts ACS/PCI DO DON’T Provide lifetime antiplatelet Rx to all patients post ACS with or without PCI. Provide DAPT with ASA + P2Y12 inhibitor to all ACS patients. Know the type of stent your patient has inserted. Consider DAPT beyond 1 year in patients with high risk of thrombosis and low risk of bleeding. Use doses of ASA above 75 – 162 mg. Discontinue DAPT prior to 1 yr without a very good reason. EVER discontinue DAPT in a patient with a Drug Eluting Stent prior to 1 yr, EVER. © 2011 - TIGC

Guideline Pearls Do’s and Don’t’s Management of patients post ACS who require surgery, diagnostic or dental procedures Guideline Pearls Do’s and Don’t’s DO DON’T Delay such procedures in patients taking DAPT. Stop clopidogrel for 7-10 days prior if it can be done so safely. Stop ASA for 7 – 10 days for bleeding high risk surgical procedures. Discontinue DAPT prior to 1 year in patients with Drug Eluting Stents EVER. Stop ASA for minor procedures including: Arthrocentesis Dental procedures Cataract surgery Skin excisions © 2011 - TIGC

Guideline Pearls Do’s and Don’t’s Minor bleeding management Guideline Pearls Do’s and Don’t’s DO DON’T If persistent check: Complete blood count INR and activated Partial thromboplastin time (aPTT) Stop antiplatelet therapy for: Eccymosis Petechia Subconjunctival hemorrhage Epistaxis Dental / gingival bleeding tranexamic acid mouthwash © 2011 - TIGC

Guideline Pearls Do’s and Don’t’s Drug interactions Guideline Pearls Do’s and Don’t’s DO DON’T Use Coxibs over traditional NSAIDs in patients taking ASA for CV prevention but only if absolutely necessary. Use PPI’s that inhibit CYP2C19 in patients taking clopidogrel or prasugrel. Use NSAIDs or Coxibs in patients at increased risk of vascular events. © 2011 - TIGC

© 2011 - TIGC